Table 5.

Univariate sensitivity analyses

	Potential savings (per inhabitant)
	Main scenario	Proportion of the population treated for hypertension increased to 9.4%	Proportion of patients with hypertension and CVD* that can take thiazides increased from 0% to 40%	Proportion of persons treated for hypertension that have CVD* increased from 40% to 50%	Proportion of persons treated for hypertension that have CVD* decreased from 40% to 30%	Proportion of persons with uncomplicated hypertension that can use thiazides decreased from 75% to 65%	Proportion of persons with uncomplicated hypertension that can use thiazides increased from 75% to 85%
Canada	$13.8 million ($0.44)	$94.8 million ($3.03)	$45.6 million ($1.46)	$-7.9 million ($-0.25)	$35.5 million ($1.14)	$-3.6 million ($-0.11)	$31.2 million ($1.00)
France	$37.4 million ($0.63)	$72.8 million ($1.23)	$51.4 million ($0.87)	$28.0 million ($0.47)	$46.9 million ($0.79)	$29.9 million ($0.50)	$45.0 million ($0.76)
Germany	$72.2 million ($0.87)	$158.9 million ($1.92)	$106.3 million ($1.28)	$48.9 million ($0.59)	$95.4 million ($1.15)	$53.6 million ($0.65)	$90.8 million ($1.10)
Norway	$10.7 million ($2.40)	$18.6 million ($4.15)	$14.3 million ($3.19)	$8.3 million ($1.86)	$13.2 million ($2.94)	$8.8 million ($1.96)	$12.7 million ($2.83)
UK	$119.7 million ($2.01)	$119.7 million ($2.01)	$199.8 million ($3.36)	$65.1 million ($1.09)	$174.3 million ($2.93)	$76.0 million ($1.28)	$163.4 million ($2.75)
US	$433.6 million ($1.57)	$808.9 million ($2.94)	$873.5 million ($3.17)	$133.6 million ($0.49)	$733.5 million ($2.66)	$193.6 million ($0.70)	$673.5 million ($2.44)

*cardiovascular disease